Eli Lilly Reports Earnings, and Maybe Weight-Loss Pill Data, on Thursday - Barron's

1. LLY leads U.S. weight-loss market with Zepbound, capturing 59% of prescriptions. 2. Earnings report expected on Thursday, anticipating $19.5 billion from Zepbound. 3. Orforglipron trial results could significantly impact LLY's future sales. 4. Legal challenges and political pressures may affect big pharma pricing strategies. 5. Analysts foresee overall sales of $94.9 billion for this quarter.